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cate that the CorPath robotic system can be successfully used to treat
PAD. Technical and clinical procedural success was obtained in all 20
patients and no device-related peri-procedural adverse events were
reported. Further studies are needed to conﬁrm the results and
elucidate their impact on outcomes.
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BACKGROUND The aim of this review is to consider evidence for the
Multilayer Flow Modulator (MFM) device in management patients
with complex thoracoabdominal aortic aneurysm (TAAA) or
dissection.
METHODS A methodical search of all health databases was con-
ducted from January 2008 to 2015 for health related and biomedical
science literature, pertaining to the MFM. Primary outcome was
aneurysm-related survival. Secondary outcomes were all-cause sur-
vival, stroke, spinal cord ischemia, renal impairment and branch
vessel patency
RESULTS A total of 15 studies (3 prospective studies, 3 observational
reviews and 9 case reports) were included. The mean age of patients
was 68.85years (þ/-12.34 years), mean aneurysm diameter was 6.67cm
(1.57cm). Technical success reported in 15 studies was 77.2 %.
Aneurysm related survival at one year was 78.7% (3.92%). One year
all-cause survival was 53.7 % (3.94%). There were no reported cases
of spinal cord ischemia or renal insult.
CONCLUSIONS The MFM appears safe in management of TAAA, once
operators abide to its Indications for Use. Since the MFM is a new
technology, there is paucity of long-term follow-up data, a lack of
comparative studies and a requirement for randomized clinical trials
and continued assessment.
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BACKGROUND The Multilayer ﬂow Modulator (MFM) increases
visceral branch outﬂow velocities by up to 8% in TAAA. The phantom
Streamliner conﬁguration generates double renal outﬂow percentage
increase. Moreover, there are differences in ﬂow lamination between
anatomical and ballerina outﬂow conﬁgurations to the iliac arterial
tree.
METHODS Out of 13 patients managed by Phantom Streamlinear
conﬁguration, of which 10 were males with mean age of 69.57þ/-9.8
years. Mean aneurysm diameter was 6.4cm with mean aneurysm
length of 26.96cm. All were ASA IV. There were four Crawford type II,
IV with AAA, seven supra/juxta-renal AAA and two complicated type B
dissection.
RESULTS Numbers of side branches covered were 61 branches with
mean of 4.7 side branch per case. Total numbers of stent used were 63
with mean of 6.25 MFM stents per case. There were no aneurysm-
related death, no paraplegia nor stroke, no renal impairment and noloss of branch patency. Quantile-Quantile plot demonstrated that
mean aortic length; diameter and thrombus are statically lower at post
op from pre op with alpha level of 5%. Moreover, there was evidence
of postoperative lower thrombus volume with no change in total
volume from pre to post. Length and diameter demonstrated the most
signiﬁcant change. The aortic lumen barely hits any signiﬁcance.
There were a decrease in mean diameter, length and thrombus
signifying a different mechanism in remodeling and laminar ﬂow.
CONCLUSIONS Phantom Streamliner is a promising technology, safe
with physiological modulation of TAAA with off the shelf availability
and must be utilized under strict IFU.
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BACKGROUND Controversy exists regarding the best revasculariza-
tion strategy for femoro-popliteal disease. We performed a network
meta-analysis of randomized controlled trials (RCTs) in patients un-
derwent peripheral endovascular intervention for femoro-popliteal
lesion to seek relative clinical outcomes of drug-coated balloon (DCB),
drug-eluting stent (DES), or bare-metal nitinol stent (BMS) compared
with balloon angioplasty (BA).
METHODS MEDLINE/PubMed, Cochrane CENTRAL, EMBASE, and
ClinicalTrials.gov were searched for RCTs comparing two treatment
modalities among DCB, DES, BMS, or BA in patients with femoro-
popliteal disease. Mixed treatment comparison model generation was
performed to directly and indirectly compare DCB, DES, and BMS on
outcomes including target lesion revascularization (TLR), primary
patency, death, and amputation at 12 and 24 month with BA. Odds
ratios with 95% conﬁdence intervals (OR [95% CIs]) were generated
with random-effect models to compare outcomes.
RESULTS Our meta-analysis included 15 RCTs with 2,843 patients that
were randomized to DCB (n¼752), DES (n¼288), BMS (n¼581), or BA
(n¼1,222). The mean age was 68.315.4, 65% were male, 41% had
coronary artery disease, 84% had hypertension, 41% had diabetes
mellitus, 11% had re-stenotic lesion, 32% had total occlusion, 7% had
critical limb ischemia, baseline ankle-brachial index of 0.680.38, and
baseline lesion length of 68.772.0 mm. At 12 month, DCB signiﬁ-
cantly reduced the risk of TLR (OR 0.29 [95% CI 0.13-0.56]), and DCB
(OR 0.41 [95% CI 0.22-0.74]) and BMS (OR 0.61 [95% CI 0.36-1.00])
signiﬁcantly improved primary patency compared with BA. DES had a
trend toward improvement in primary patency and TLR compared
with BA.
